SHAREHOLDER ALERT: WeissLaw LLP Investigates Vical Incorporated Acquisition

NEW YORK, June 12, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Vical Incorporated ("VICL" or the "Company") VICL in connection with the proposed acquisition of the Company by Brickell Biotech, Inc. 

If you are a shareholder of VICL who wishes to discuss the investigation or have any questions about this notice and your rights or interests, please contact:

Joshua Rubin, Esq.

WeissLaw LLP

1500 Broadway, 16^th Floor

New York, NY  10036

(212) 682-3025

(888)593-4771

stockinfo@weisslawllp.com

Or visit our website

http://www.weisslawllp.com/vical-incorporated/

Or follow us on Twitter @MarketsAlert

WeissLaw is investigating whether VICL's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at close of the transaction, VICL shareholders will own only 40% of the combined company.

WeissLaw is also investigating whether VICL's Board conducted a fair process in agreeing to the proposed merger, whether the proposed merger undervalues the Company, and whether all material information related to the proposed merger is fully and fairly disclosed. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-vical-incorporated-acquisition-300866502.html

SOURCE WeissLaw LLP